



ESMO 2017 Industry Satellite Symposium
Sponsored by Clovis Oncology

The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture

Sunday 10 September 2017, 18:30–20:00

IFEMA – Feria de Madrid, Hall 4, Bilbao Auditorium, Madrid, Spain

Refreshments will be provided prior to the meeting outside the Bilbao Auditorium at 18:00

Chair's Introduction and Case Study Presentation

Ana Oaknin, MD PhD

Vall d'Hebron University Hospital, Barcelona, Spain

The Current Landscape of Platinum-Sensitive Relapsing Ovarian Cancer: European and US Perspectives

Michael J. Birrer, MD PhD

University of Alabama at Birmingham Comprehensive Cancer Center, USA

The Role of PARP Inhibitors in Advanced Ovarian Cancer: Where Are We Now?

Jonathan Ledermann, BSc MD FRCP

UCL Cancer Institute at University College London, UK

BRCA and HRD: To Test or Not to Test, Is that the Question?

Iain McNeish, PhD FRCP

University of Glasgow, UK

BRCA and Beyond! Future Directions for Enhancing PARP Inhibitor Therapy

Domenica Lorusso, MD PhD

Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy

Case Study Discussion and Audience Feedback

Ana Oaknin

Panel Q&A and Close

Clovis Oncology no tiene un medicamento autorizado en España, solo tiene un medicamento autorizado en los Estados Unidos de América.

Clovis Oncology does not have an approved medicine in Spain, and only has an approved medicine in the United States of America.